Location History:
- Albany, CA (US) (2012)
- Fremont, CA (US) (2015)
Company Filing History:
1 out of 245 
1 out of 3,923 
1 out of 84 Years Active: 2012-2015
Title: Innovations of Xiaofeng Lu in Pharmaceutical Compositions
Introduction
Xiaofeng Lu is a notable inventor based in Fremont, CA (US). He has made significant contributions to the field of pharmaceutical compositions, particularly in the development of antagonist anti-CD40 antibodies. With a total of 2 patents, his work focuses on innovative methods for treating proliferative diseases and autoimmune conditions.
Latest Patents
Xiaofeng Lu's latest patents include groundbreaking compositions and methods. One patent details stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody, which serves as a therapeutically active component. These compositions are designed to maintain a pH between about 5.0 and 7.0, utilizing a buffering agent and arginine-HCl to achieve near isotonicity. This innovation is particularly useful in treating diseases with autoimmune and inflammatory components.
Another patent focuses on the therapeutic methods for diseases mediated by CD40 signaling. It involves administering a therapeutically effective amount of an antagonist anti-CD40 antibody or its antigen-binding fragment to patients. This antibody is designed to inhibit the proliferation and differentiation of human CD40-expressing cells, such as B cells, thereby providing a beneficial therapeutic effect.
Career Highlights
Throughout his career, Xiaofeng Lu has worked with prominent companies in the pharmaceutical industry, including Novartis Vaccines & Diagnostics and Novartis AG. His experience in these organizations has contributed to his expertise in developing innovative therapeutic solutions.
Collaborations
Xiaofeng Lu has collaborated with notable colleagues, including Bao-lu Chen and Li Long. These partnerships have likely enhanced his research and development efforts in the field of pharmaceutical innovations.
Conclusion
Xiaofeng Lu's contributions to the field of pharmaceutical compositions, particularly through his patents on antagonist anti-CD40 antibodies, demonstrate his commitment to advancing medical treatments. His work continues to impact the development of therapies for complex diseases.